



Global Antimicrobial Resistance: What Are the Current Emerging Threats?

Guest Editor:

Dr. Laura J. Rojas

Case Western Reserve University
School of Medicine - Louis Stokes
Cleveland VA Medical Center,
Cleveland, OH, USA

Deadline for manuscript
submissions:

closed (30 June 2021)

Message from the Guest Editor

Antimicrobial resistance (AMR) is a complex public health challenge impacting all regions of the world. In addition to being a natural evolutionary phenomenon, AMR is increasingly being accelerated by selective pressure exerted as a result of the use and misuse of antibiotics in humans and animals. Fighting this threat is a priority that requires a global approach across multiple sectors beyond healthcare, including the food supply chain and the environment.

The scientific community has made significant advances in increasing their knowledge about the most urgent threats, primarily in clinical settings; however new mechanisms and new emerging bacterial threats are constantly being discovered within these as well as other settings.

With this global approach in mind, this Special Issue seeks submissions highlighting the new threats that we need to be on the lookout for: novel antibiotic resistance mechanisms, emerging pathogens, novel ‘high-risk clones’, or increasing rates of resistance in organisms previously considered less of a concern, especially from regions of the world where epidemiological data are scarce.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi